Guang-Yuan Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guang-Yuan Ma has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Wei Cao
Shaanxi Key Laboratory of Natural Products & Chemical Biology, School of Chemistry & Pharmacy, Northwest A&F University, Yangling, 712100, China; Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, School of Pharmacy, Air Force Medical University, Xi'an, 710032, China
2 shared publications - Xiao-Qiang Li
Department of Chinese Materia Medica and Natural Medicines, School of Pharmacy, Air Force Medical University, Xi'an,Shaanxi, 710032, China
2 shared publications - Chen Ye
Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi’an, China
1 shared publication Detai Liu
Shaanxi Key Laboratory of Natural Products & Chemical Biology School of Chemistry & Pharmacy Northwest A&F University Yangling 712100 China
1 shared publicationDianchao Dong
Shaanxi Key Laboratory of Natural Products & Chemical Biology School of Chemistry & Pharmacy Northwest A&F University Yangling 712100 China
1 shared publication- Huinan Zhang
Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi’an, China
1 shared publication
Latest Publications
- 1 April 2023
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 15 (7) , 629-646
The Synthesis and Effects of a Novel TRPC6 inhibitor, BP3112, on Hepatocellular Carcinoma
Aims: Transient receptor potential canonical-6 (TRPC6) is a therapeutic target for hepatocellular carcinoma. The authors aimed to synthesize and determine whether indole-2-carboxamide derivatives h...
- 1 April 2023
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 15 (7) , 629-646
The Synthesis and Effects of a Novel TRPC6 inhibitor, BP3112, on Hepatocellular Carcinoma
Aims: Transient receptor potential canonical-6 (TRPC6) is a therapeutic target for hepatocellular carcinoma. The authors aimed to synthesize and determine whether indole-2-carboxamide derivatives h...
- Open Access
- 12 October 2021
- Published by Springer Nature in Oncogenesis
- Vol. 10 (10) , 1-13
TRPC1 promotes the genesis and progression of colorectal cancer via activating CaM-mediated PI3K/AKT signaling axis
Transient receptor potential canonical (TRPC) channels are the most prominent nonselective cation channels involved in various diseases. However, the function, clinical significance, and molecular mechanism of TRPCs in colorectal cancer (CRC) progression remain unclear. In this study, we identified that TRPC1 was the major variant gene of the TRPC family in CRC patients. TRPC1 was upregulated in CRC tissues compared with adjacent normal tissues and high expression of TRPC1 was associated with more aggressive tumor progression and poor overall survival. TRPC1 knockdown inhibited cell proliferation, cell-cycle progression, invasion, and migration in vitro, as well as tumor growth in vivo; whereas TRPC1 overexpression promoted colorectal tumor growth and metastasis in vitro and in vivo. In addition, colorectal tumorigenesis was significantly attenuated in Trpc1-/- mice. Mechanistically, TRPC1 could enhance the interaction between calmodulin (CaM) and the PI3K p85 subunit by directly binding to CaM, which further activated the PI3K/AKT and its downstream signaling molecules implicated in cell cycle progression and epithelial-mesenchymal transition. Silencing of CaM attenuated the oncogenic effects of TRPC1. Taken together, these results provide evidence that TRPC1 plays a pivotal oncogenic role in colorectal tumorigenesis and tumor progression by activating CaM-mediated PI3K/AKT signaling axis. Targeting TRPC1 represents a novel and specific approach for CRC treatment.
- 12 October 2021
- Published by Springer Nature in Oncogenesis
- Vol. 10 (10) , 1-13
Open AccessTRPC1 promotes the genesis and progression of colorectal cancer via activating CaM-mediated PI3K/AKT signaling axis
Transient receptor potential canonical (TRPC) channels are the most prominent nonselective cation channels involved in various diseases. However, the function, clinical significance, and molecular mechanism of TRPCs in colorectal cancer (CRC) progression remain unclear. In this study, we identified that TRPC1 was the major variant gene of the TRPC family in CRC patients. TRPC1 was upregulated in CRC tissues compared with adjacent normal tissues and high expression of TRPC1 was associated with more aggressive tumor progression and poor overall survival. TRPC1 knockdown inhibited cell proliferation, cell-cycle progression, invasion, and migration in vitro, as well as tumor growth in vivo; whereas TRPC1 overexpression promoted colorectal tumor growth and metastasis in vitro and in vivo. In addition, colorectal tumorigenesis was significantly attenuated in Trpc1-/- mice. Mechanistically, TRPC1 could enhance the interaction between calmodulin (CaM) and the PI3K p85 subunit by directly binding to CaM, which further activated the PI3K/AKT and its downstream signaling molecules implicated in cell cycle progression and epithelial-mesenchymal transition. Silencing of CaM attenuated the oncogenic effects of TRPC1. Taken together, these results provide evidence that TRPC1 plays a pivotal oncogenic role in colorectal tumorigenesis and tumor progression by activating CaM-mediated PI3K/AKT signaling axis. Targeting TRPC1 represents a novel and specific approach for CRC treatment.